BACKGROUND: The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian Childhood Immunization Program in 2006. A substantial effectiveness of PCV7 immunization against invasive pneumococcal disease has been demonstrated, whereas evidence of its impact on respiratory tract infections are less consistent. METHODS: This study included children participating in the Norwegian Mother and Child Cohort Study, which recruited pregnant women between 1999 and 2008. Maternal report of acute otitis media (AOM), lower respiratory tract infections (LRTIs) and asthma in the child was compared by PCV7 immunization status, as obtained from the Norwegian Immunization Registry. Generalized linear models with the log-link function were used to report adjusted relative risks (RRs) and 95% confidence intervals (CIs). RESULTS: For children who had received 3 or more PCV7 immunizations by 12 months of age, the adjusted RRs of AOM and LRTIs between 12 and 18 months were 0.86 (95% CI: 0.81, 0.91) and 0.78 (95% CI: 0.70, 0.87) respectively, when compared with nonimmunized children. A reduced risk of AOM, RR 0.92 (95% CI: 0.90, 0.94), and LRTIs, RR 0.75 (95% CI: 0.71, 0.80), between 18 and 36 months of age was also identified among children who had received 3 or more immunizations by 18 months of age. No association was seen between PCV7 immunization and asthma at 36 months of age. CONCLUSION: Reduced incidences of AOM and LRTIs before 36 months of age were observed among children immunized with PCV7 through the childhood immunization program.
BACKGROUND: The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian Childhood Immunization Program in 2006. A substantial effectiveness of PCV7 immunization against invasive pneumococcal disease has been demonstrated, whereas evidence of its impact on respiratory tract infections are less consistent. METHODS: This study included children participating in the Norwegian Mother and Child Cohort Study, which recruited pregnant women between 1999 and 2008. Maternal report of acute otitis media (AOM), lower respiratory tract infections (LRTIs) and asthma in the child was compared by PCV7 immunization status, as obtained from the Norwegian Immunization Registry. Generalized linear models with the log-link function were used to report adjusted relative risks (RRs) and 95% confidence intervals (CIs). RESULTS: For children who had received 3 or more PCV7 immunizations by 12 months of age, the adjusted RRs of AOM and LRTIs between 12 and 18 months were 0.86 (95% CI: 0.81, 0.91) and 0.78 (95% CI: 0.70, 0.87) respectively, when compared with nonimmunized children. A reduced risk of AOM, RR 0.92 (95% CI: 0.90, 0.94), and LRTIs, RR 0.75 (95% CI: 0.71, 0.80), between 18 and 36 months of age was also identified among children who had received 3 or more immunizations by 18 months of age. No association was seen between PCV7 immunization and asthma at 36 months of age. CONCLUSION: Reduced incidences of AOM and LRTIs before 36 months of age were observed among children immunized with PCV7 through the childhood immunization program.
Authors: Terhi Kilpi; Heidi Ahman; Jukka Jokinen; Kari S Lankinen; Arto Palmu; Heljä Savolainen; Marko Grönholm; Maija Leinonen; Tapani Hovi; Juhani Eskola; Helena Käyhty; Norman Bohidar; Jerald C Sadoff; P Helena Mäkelä Journal: Clin Infect Dis Date: 2003-10-07 Impact factor: 9.079
Authors: Bruce Fireman; Steven B Black; Henry R Shinefield; Janelle Lee; Edwin Lewis; Paula Ray Journal: Pediatr Infect Dis J Date: 2003-01 Impact factor: 2.129
Authors: Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell Journal: Pediatr Infect Dis J Date: 2002-09 Impact factor: 2.129
Authors: Ian C Michelow; Kurt Olsen; Juanita Lozano; Nancy K Rollins; Lynn B Duffy; Thedi Ziegler; Jaana Kauppila; Maija Leinonen; George H McCracken Journal: Pediatrics Date: 2004-04 Impact factor: 7.124
Authors: Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Katherine L O'Brien; Lawrence H Moulton; Raymond Reid; Robert Weatherholtz; Jane Oski; Laura Brown; Gaurav Kumar; Alan Parkinson; Diana Hu; Jill Hackell; Ih Chang; Robert Kohberger; George Siber; Mathuram Santosham Journal: Lancet Date: 2003-08-02 Impact factor: 79.321
Authors: Alan C Kinlaw; Til Stürmer; Jennifer L Lund; Lars Pedersen; Michael D Kappelman; Julie L Daniels; Trine Frøslev; Christina D Mack; Henrik Toft Sørensen Journal: Pediatrics Date: 2017-08-14 Impact factor: 7.124
Authors: Alexandre C Fortanier; Roderick P Venekamp; Marieke L A de Hoog; Cuno S P M Uiterwaal; Anne C van der Gugten; Cornelis K van der Ent; Arno W Hoes; Anne G M Schilder Journal: PLoS One Date: 2015-04-07 Impact factor: 3.240
Authors: Alexandre C Fortanier; Roderick P Venekamp; Chantal Wb Boonacker; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux Journal: Cochrane Database Syst Rev Date: 2019-05-28
Authors: Joline Lh de Sévaux; Roderick P Venekamp; Vittoria Lutje; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux Journal: Cochrane Database Syst Rev Date: 2020-11-24
Authors: Thomas Lampert; Jens Hoebel; Benjamin Kuntz; Jonas D Finger; Heike Hölling; Michael Lange; Elvira Mauz; Gert B M Mensink; Christina Poethko-Müller; Anja Schienkiewitz; Anne Starker; Johannes Zeiher; Bärbel-Maria Kurth Journal: J Health Monit Date: 2019-03-14